Success Stories: NAILG Guides Gene Editing Expert to NIW Approval for Groundbreaking Neuromuscular Disease Research

Client’s Testimonial:

“I am exceedingly satisfied with the Chen Immigration Team during the preparation of my case. Their responses were both professional and prompt, providing numerous practical suggestions. I am grateful to the team members for their dedication and guidance throughout my case.”

On January 28^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Analyst in the Field of Neuromuscular Diseases (Approval Notice).

General Field: Neuromuscular Diseases

Position at the Time of Case Filing: Research Analyst

Country of Origin: China

State of Residence at the Time of Filing: Indiana

Approval Notice Date: January 28^th, 2025

Processing Time: 4 months, 2 days (Premium Processing Requested)

Case Summary:

NAILG successfully obtained NIW approval for a research analyst whose work in neuromuscular diseases is transforming the possibilities of treatment for hereditary conditions. Trained in both medicine and research, this expert focuses on creating gene editing therapies that directly target the genetic roots of congenital disorders. The goal is not only to enhance patient outcomes but also to expand treatment options and improve quality of life for those affected by severe neuromuscular diseases.

From Scientific Discovery to Patient Care
The research at the heart of this case bridges an essential gap between laboratory insights and practical therapies. By refining the use of advanced technologies such as CRISPR-Cas9, this scientist has demonstrated how gene editing can be applied with greater precision and effectiveness in clinical interventions. These contributions matter deeply to patients suffering from conditions like Duchenne muscular dystrophy, where improved therapies can slow disease progression, improve prognosis, and reduce the long-term economic burden on families and the healthcare system.

Recognition and Evidence of Impact
The petition highlighted substantial accomplishments, including 17 peer-reviewed journal articles (5 first-authored), 6 conference abstracts (3 first-authored), and 2 preprints, with the body of work already cited 539 times. In addition, service as a reviewer for at least 5 manuscripts underscored this expert’s standing in the scientific community. The research has received competitive support from both the National Institutes of Health (NIH) and the Parent Project Muscular Dystrophy (PPMD), affirming its importance to national health priorities.

As one testimonial noted, “In summation, [Client]’s leadership in neuromuscular diseases is clearly demonstrated by her work in identifying the underlying genetic mechanisms of hereditary muscular atrophy and revealing targets for interventions using advanced technologies such as CRISPR-Cas9. It is easy to anticipate that [Client] will continue to produce additional valuable research, both driving progress in the field and bringing immense benefits to national and international concerns.”

Securing Approval and Looking Ahead
The approval of this NIW petition is an acknowledgment of both the groundbreaking nature of the research and its clear relevance to U.S. public health priorities. Through NAILG’s representation, the case demonstrated how developing gene editing therapies for congenital neuromuscular diseases is indispensable for advancing healthcare in the United States. This success ensures that the researcher can continue to build on her pioneering work, driving forward therapeutic innovations that promise lasting benefits for patients and the medical community alike.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.